Literature DB >> 1718687

Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I).

M Koltai1, D Hosford, P Guinot, A Esanu, P Braquet.   

Abstract

This review is an attempt to summarise recent data on platelet activating factor (PAF) and PAF antagonists from 1988 to the present. This period saw a burst in research activity focused predominantly on the effect of PAF in various organs. The effect of PAF and its antagonists was further intensively studied in vitro on isolated platelets, leucocytes, macrophages and endothelial cells. From these and earlier data, based on the catastrophe theory of Thom and Zeeman, a new concept on the interaction between PAF and various cytokines could be recognised as an important mechanism of action of the phospholipid mediator, suggesting the existence of an autocatalytic feedback network through which PAF can influence cellular function under certain pathophysiological conditions. This mechanism can be regarded as the culmination of our recent knowledge on the role of PAF, and may influence the possible clinical implications of PAF antagonists in the near future. It is recognised that PAF is released in shock and ischaemic states, and that PAF antagonists can protect the heart and brain against ischaemic injury. Therefore, in contrast to the previous period, which was predominantly devoted to the elucidation of the role of PAF in immediate hypersensitivity reactions, studies performed on cerebral, myocardial and intestinal ischaemia as well as in various shock conditions have concentrated on entirely new aspects of the effect of PAF antagonists, emphasising the significance of the inflammatory process and cell-to-cell interactions in these pathophysiological states. This has led to a re-evaluation of the experimental data previously accumulated. At the same time, these new trends in PAF and PAF antagonist research have explored further possibilities for the application of PAF antagonists in clinical practice. Attention has been focused on the physiological role of PAF as a signal molecule, especially between the neuroendocrine system and related sensory organs. The recognition of the significance of PAF in mammalian reproduction is fascinating and may lead to new clinical applications of PAF antagonists. It appears probable that, like eicosanoids, PAF is involved in a great variety of membrane-dependent processes that play a fundamental role in the maintenance of homeostasis. PAF research has provided several potent natural and synthetic antagonists which may facilitate the clinical application of these drugs in the near future.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718687     DOI: 10.2165/00003495-199142010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves.

Authors:  M B Bastos da Silva; P Gustin; F Herion; R Raskinet; J L David; T Gougnard; G Plomteux; D Desmecht; P Lekeux
Journal:  Vet Res Commun       Date:  1997-10       Impact factor: 2.459

2.  Cover picture. The precious qualities of a "fossil" tree.

Authors:  Jie Ma; Yang Zhao
Journal:  Childs Nerv Syst       Date:  2009-07       Impact factor: 1.475

Review 3.  Treatment of bronchospastic disorders in the 1990s. What does the future hold?

Authors:  P G Gianaris; J A Golish
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

4.  Effect of platelet-activating factor on secretion of mucous glycoprotein from chinchilla middle ear epithelial cells in vitro.

Authors:  J Lin; Y Kim; C Lees; S K Juhn
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

5.  Flow cytometric assay of phagocytic activity of human neutrophils and monocytes in whole blood by neutral red uptake.

Authors:  P Antal; S Sipka; P Surányi; I Csipo; T Seres; L Maródi; G Szegedi
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

6.  Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.

Authors:  M Giral; D Balsa; R Ferrando; M Merlos; J Garcia-Rafanell; J Forn
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Platelet secretion from dense and alpha-granules in vitro in migraine with or without aura.

Authors:  G D'Andrea; L Hasselmark; M Alecci; A Cananzi; F Perini; K M Welch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

8.  PAF-AH Catalytic Subunits Modulate the Wnt Pathway in Developing GABAergic Neurons.

Authors:  Idit Livnat; Danit Finkelshtein; Indraneel Ghosh; Hiroyuki Arai; Orly Reiner
Journal:  Front Cell Neurosci       Date:  2010-05-28       Impact factor: 5.505

9.  Structurally diverse metal coordination compounds, bearing imidodiphosphinate and diphosphinoamine ligands, as potential inhibitors of the platelet activating factor.

Authors:  Alexandros B Tsoupras; Maria Roulia; Eleftherios Ferentinos; Ioannis Stamatopoulos; Constantinos A Demopoulos; Panayotis Kyritsis
Journal:  Bioinorg Chem Appl       Date:  2010-06-28       Impact factor: 7.778

10.  The role of inflammatory mediators in the pathogenesis of otitis media and sequelae.

Authors:  Steven K Juhn; Min-Kyo Jung; Mark D Hoffman; Brian R Drew; Diego A Preciado; Nicholas J Sausen; Timothy T K Jung; Bo Hyung Kim; Sang-Yoo Park; Jizhen Lin; Frank G Ondrey; David R Mains; Tina Huang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-09-30       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.